Melane Sampson, Author at BioTuesdays

Executive Moves

Cibus elects Craig Wichner to BOD

Cibus (NASDAQ: CBUS) has announced the election of Craig Wichner to its Board of Directors (BOD) and the board’s strategy committee. “Craig brings an exceptional combination of financial acumen, strategic discipline...

November 11, 2025

Feature

Experity placing human connection at the center of AI-driven urgent care

Closely held Experity Health is shaping the future of healthcare by embedding AI into urgent care hubs across the U.S. to improve patient access, speed clinical visits, and elevate care quality.

November 11, 2025

Developments

PharmaJet inks agreement with EVA Pharma to provide needle-free injection systems to support routine polio immunization in Egypt

Closely held PharmaJet has announced that it has signed a distribution agreement with ATR, an affiliate to closely held EVA Pharma. The agreement, signed in Frankfurt at the CPHI meeting on October 30, 2025, includes...

November 6, 2025

Developments

Advicenne submits registration application to FDA for Sibnayal in dRTA

Advicenne (Euronext Growth Paris: FR0013296746—ALDVI) has announced the submission of a registration application to the FDA for Sibnayal—a fixed-dose combination of potassium citrate and potassium bicarbonate—for the...

November 5, 2025

Developments

Surmodics reports outcomes from registry evaluating Pounce in limb ischemia

Surmodics (NASDAQ: SRDX) has announced outcomes from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia in the PROWL registry study evaluating its Pounce thrombectomy platform. The...

November 5, 2025

Developments

Wellgistics enters LOI to acquire Kare RX digital hub

Wellgistics Health (NASDAQ: WGRX) has announced that it has entered into a non-binding letter of intent (LOI) to acquire Kare RX—an AI-based digital hub—from closely held Kare PharmaTech. According to Wellgistics, Kare...

November 5, 2025

Developments

GeoVax connects IDSA COVID-19 guidance to GEO-CM04S1 clinical data

GeoVax Labs (NASDAQ: GOVX) has highlighted that its recent Phase 2 findings for GEO-CM04S1 aligns with Infectious Diseases Society of America (IDSA) guidelines prioritizing vaccination for immunocompromised individuals...

October 29, 2025

Developments

APO grants new patent for Moleculin’s Annamycin

Moleculin Biotech (NASDAQ: MBRX) has announced that the Australian Patent Office (APO) has granted a patent with claims covering certain preliposomal Annamycin lyophilizates with improved stability and high purity...

October 29, 2025

Feature

Immuneering outpacing cancer with a novel approach to improving overall survival

Immuneering (NASDAQ: IMRX) is challenging conventional approaches of sustained inhibition in oncology by pioneering a novel class of therapies designed to outsmart cancer’s ability to adapt. With a proprietary platform...

October 28, 2025

Executive Moves

Mary-Elizabeth Gifford joins Clearmind as Chief of Global Impact

Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced the appointment of Mary-Elizabeth Gifford as chief of global impact. Prior to joining Clearmind, Gifford served as chief of global impact at Psyence BioMed, a...

October 27, 2025

Author - Melane Sampson

Cibus elects Craig Wichner to BOD

Experity placing human connection at the center of AI-driven urgent care

PharmaJet inks agreement with EVA Pharma to provide needle-free injection systems to support routine polio immunization in Egypt

Advicenne submits registration application to FDA for Sibnayal in dRTA

Surmodics reports outcomes from registry evaluating Pounce in limb ischemia

Wellgistics enters LOI to acquire Kare RX digital hub

GeoVax connects IDSA COVID-19 guidance to GEO-CM04S1 clinical data

APO grants new patent for Moleculin’s Annamycin

Immuneering outpacing cancer with a novel approach to improving overall survival

Mary-Elizabeth Gifford joins Clearmind as Chief of Global Impact

Subscribe